For the Inventor, By the Inventor

Enter assignee name

Ontario, Canada

Lunella Biotech, Inc.

Calculating rank

USPTO Granted Patents = 32

% Expired Patents = 3.1

CIPO Patents = 1

EPO Patents = 12

Forward Citations = 8

Loading Chart...

Loading Chart...

7 inventors (with patents filed for the assignee):

Michael P Lisanti (21 out of 23 patents)

Federica Sotgia (21 out of 22 patents)

Federica Sotgia (10 out of 10 patents)

4. Michael P Lisanti (10 out of 10 patents)

5. Marco Fiorillo (4 out of 4 patents)

6. Jussi Kangasmetsa (4 out of 4 patents)

7. Luma G Magalhães (2 out of 2 patents)

8. Federica Sotgia (1 out of 1 patent)

9. Michael P Lisanti (1 out of 1 patent)

Core Competencies:

Tumor Metastasis

Mitochondrial Inhibitors

CDK 4/6 Inhibitors

Cancer Stem Cells

Senolytic Drugs

Endocrine Resistance

Combination Therapies

Targeted Inhibitors

Mitochondrial Biogenesis

Hyper-Metabolic Phenotype

Companion Diagnostics

Synthetic Lethal Therapy

32 patents: Sort by Forward Citations

1. 12773418 - Alkyl-TPP compounds for mitochondria targeting and anti-cancer treatments (2026-10-27),

2. 12766116 - Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast (2026-10-20),

3. 12728104 - Therapeutic methods for preventing tumor metastasis and tumor recurrence (2026-09-08),

4. 12723029 - Mitochondrial ATP inhibitors targeting the gamma subunit prevent metastasis (2026-09-01),

5. 12553092 - Energetic cancer stem cells (E-CSCS): a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energy (2026-02-17),

6. 12358920 - Substituted pyrrolo[2,3-d]pyrimidines as selective CDK 4/6 inhibitors (2025-07-15),

7. 12319690 - Selective CDK 4/6 inhibitor cancer therapeutics (2025-06-03),

8. 12208111 - Azithromycin and roxithromycin derivtives as senolytic drugs (2025-01-28),

9. 12188936 - Biomarkers and therapeutics for endocrine therapy resistance (2025-01-07),

10. 12006553 - Companion diagnostics for mitochondrial inhibitors (2024-06-11),

11. 11964983 - Selective CDK4/6 inhibitor cancer therapeutics (2024-04-23),

12. 11957700 - Azithromycin and roxithromycin derivatives as senolytic drugs (2024-04-16),

13. 11918597 - Triple combination therapies for anti-aging (2024-03-05),

14. 11865130 - Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells (2024-01-09),

15. 11865124 - Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCS) (2024-01-09),

Company Overview

Lunella Biotech, Inc. is a biotechnology company based in Ontario, CA, focused on developing innovative therapies for rare and complex diseases. The organization specializes in harnessing advanced genetic and molecular technologies to create targeted treatments that address unmet medical needs. With a commitment to scientific excellence, Lunella aims to transform the landscape of healthcare through its cutting-edge research and development efforts, ultimately improving patient outcomes and quality of life.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

32 Patents

#7 in Ontario

#10,618 in Canada

#20,722 in the World

Ontario, Canada

Lunella Biotech, Inc.

Forward Citations = 8

7 inventors:

Michael P Lisanti (21 out of 23 patents)

Federica Sotgia (21 out of 22 patents)

Federica Sotgia (10 out of 10 patents)

4. Michael P Lisanti (10 out of 10 patents)

5. Marco Fiorillo (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Lunella Biotech, Inc.. Retrieved from https://idiyas.com/company/lunella-biotech

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…